1932

Abstract

The prescribing of opioid analgesics for pain management—particularly for management of chronic noncancer pain (CNCP)—has increased more than fourfold in the United States since the mid-1990s. Yet there is mounting evidence that opioids have only limited effectiveness in the management of CNCP, and the increased availability of prescribed opioids has contributed to upsurges in opioid-related addiction cases and overdose deaths. These concerns have led to critical revisiting and modification of prior pain management practices (e.g., guidelines from the Centers for Disease Control and Prevention), but the much-needed changes in clinical practice will be facilitated by a better understanding of the pharmacology and behavioral effects of opioids that underlie both their therapeutic effects (analgesia) and their adverse effects (addiction and overdose). With these goals in mind, this review first presents an overview of the contemporary problems associated with opioid management of CNCP and the related public health issues of opioid diversion, overdose, and addiction. It then discusses the pharmacology underlying the therapeutic and main adverse effects of opioids and its implications for clinical management of CNCP within the framework of recent clinical guidelines for prescribing opioids in the management of CNCP.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-011817-044739
2018-01-29
2024-04-17
Loading full text...

Full text loading...

/deliver/fulltext/med/69/1/annurev-med-011817-044739.html?itemId=/content/journals/10.1146/annurev-med-011817-044739&mimeType=html&fmt=ahah

Literature Cited

  1. Merskey H, Bond M, Bonica J. 1.  et al.International Association for the Study of Pain, Subcommittee on Taxonomy. 1986. Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms Seattle: Intl. Assoc. Stud. Pain
  2. Andersson GB. 2.  1999. Epidemiological features of chronic low-back pain. Lancet 354:9178581–85 [Google Scholar]
  3. 3. Institute of Medicine. 2011. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education and Research Washington, DC: Natl. Acad. Press
  4. Johannes CB, Le TK, Zhou X. 4.  et al. 2010. The prevalence of chronic pain in United States adults: results of an Internet-based survey. J. Pain 11:111230–39 [Google Scholar]
  5. 5. Centers for Disease Control and Prevention. 2001. Prevalence of disabilities and associated health conditions among adults—United States, 1999.. Morb. Mortal. Wkly. Rep. 50:7120–25 [Google Scholar]
  6. Gureje O, Von Korff M, Simon GE, Gater R. 6.  1998. Persistent pain and well-being: a World Health Organization Study in Primary Care. JAMA 280:2147–51 [Google Scholar]
  7. 7. Centers for Disease Control and Prevention. 2011. Vital signs: overdoses of prescription opioid relievers. United States 1999–2008. Morb. Mortal. Wkly. Rep. 60:431487–92 [Google Scholar]
  8. Chou R, Fanciullo GJ, Fine PG. 8.  et al. 2009. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J. Pain 10:2113–30 [Google Scholar]
  9. Allan L, Richarz U, Simpson K, Slappendel R. 9.  2005. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back pain. Spine 30:222484–90 [Google Scholar]
  10. Kalso E, Edwards JE, Moore RA, McQuay HJ. 10.  2004. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 112:3372–80 [Google Scholar]
  11. Moore RA, McQuay HJ. 11.  2005. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res. Ther. 7:5R1046–51 [Google Scholar]
  12. Noble M, Tregear SJ, Treadwell JR, Schoelles K. 12.  2008. Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety. J. Pain Symptom Manag. 35:2214–28 [Google Scholar]
  13. 13. Centers for Disease Control and Prevention. 2016. Prescription opioid overdose data https://www.cdc.gov/drugoverdose/data/overdose.html
  14. Knowlton A, Weir BW, Hazzard F. 14.  et al. 2013. EMS runs for suspected opioid overdose: implications for surveillance and prevention. Prehosp. Emerg. Care 17:3317–29 [Google Scholar]
  15. 15. Substance Abuse and Mental Health Services Administration. 2016. Key substance use and mental health indicators in the United States: results from the 2015 National Survey on Drug Use and Health https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR1-2015/NSDUH-FFR1-2015/NSDUH-FFR1-2015.pdf
  16. Deshpande A, Furlan A, Mailis-Gagnon A. 16.  et al. 2007. Opioids for chronic low-back pain. Cochrane Database Syst. Rev. 3:CD004959 [Google Scholar]
  17. Devulder J, Richarz U, Nataraja SH. 17.  2005. Impact of long-term use of opioids on quality of life in patients with chronic, non-malignant pain. Curr. Med. Res. Opin. 21:101555–68 [Google Scholar]
  18. Eisenberg E, McNicol ED, Carr DB. 18.  2005. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. JAMA 293:243043–52 [Google Scholar]
  19. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. 19.  2006. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. Can. Med. Assoc. J. 174:111589–94 [Google Scholar]
  20. Hollingshead J, Duhmke RM, Cornblath DR. 20.  2006. Tramadol for neuropathic pain. Cochrane Database Syst. Rev 3:CD003726 [Google Scholar]
  21. Martell BA, O'Connor PG, Kerns RD. 21.  et al. 2007. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann. Intern. Med. 146:2116–27 [Google Scholar]
  22. Sandoval JA, Furlan AD, Mailis-Gagnon A. 22.  2005. Oral methadone for chronic noncancer pain: a systematic literature review of reasons for administration, prescription patterns, effectiveness, and side effects. Clin. J. Pain 21:6503–12 [Google Scholar]
  23. Lee BH, Park JO, Suk KS. 23.  et al. 2013. Pre-emptive and multi-modal perioperative pain management may improve quality of life in patients undergoing spinal surgery. Pain Physician 16:3E217–26 [Google Scholar]
  24. Prabhakar A, Cefalu JN, Rowe JS. 24.  et al. 2017. Techniques to optimize multimodal analgesia in ambulatory surgery. Curr. Pain Headache Rep. 21:524 [Google Scholar]
  25. Varrassi G, Hanna M, Macheras G. 25.  et al. 2017. Multimodal analgesia in moderate-to-severe pain: a role for a new fixed combination of dexketoprofen and tramadol. Curr. Med. Res. Opin 33:1165–73 [Google Scholar]
  26. Chou R, Turner JA, Devine EB. 26.  et al. 2015. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann. Intern. Med. 162:4276–86 [Google Scholar]
  27. Hale ME, Fleischmann R, Salzman R. 27.  et al. 1999. Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain. Clin. J. Pain 15:3179–83 [Google Scholar]
  28. Matsumoto AK, Babul N, Ahdieh H. 28.  2005. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial. Pain Med 6:5357–66 [Google Scholar]
  29. Nicholson B, Ross E, Sasaki J, Weil A. 29.  2006. Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain. Curr. Med. Res. Opin. 22:81503–14 [Google Scholar]
  30. Niemann T, Madsen LG, Larsen S, Thorsgaard N. 30.  2000. Opioid treatment of painful chronic pancreatitis. Int. J. Pancreatol. 27:3235–40 [Google Scholar]
  31. Rauck RL, Bookbinder SA, Bunker TR. 31.  et al. 2007. A randomized, open-label, multicenter trial comparing once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-release tablets) for the treatment of chronic, moderate to severe low back pain: improved physical functioning in the ACTION trial. J. Opioid Manag. 3:135–43 [Google Scholar]
  32. Rauck RL, Bookbinder SA, Bunker TR. 32.  et al. 2006. The ACTION study: a randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain. J. Opioid Manag 2:3155–66 [Google Scholar]
  33. Skolnick P, Volkow ND. 33.  2016. Re-energizing the development of pain therapeutics in light of the opioid epidemic. Neuron 92:2294–97 [Google Scholar]
  34. Finnerup NB, Attal N, Haroutounian S. 34.  et al. 2015. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 14:2162–73 [Google Scholar]
  35. Derry S, Gill D, Phillips T, Moore RA. 35.  2012. Milnacipran for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst. Rev. 3:CD008244 [Google Scholar]
  36. Arnold LM, Russell IJ, Diri EW. 36.  et al. 2008. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J. Pain 9:9792–805 [Google Scholar]
  37. Linde K, Allais G, Brinkhaus B. 37.  et al. 2016. Acupuncture for the prevention of tension-type headache. Cochrane Database Syst. Rev. 4:CD007587 [Google Scholar]
  38. Sun Y, Gan TJ, Dubose JW, Habib AS. 38.  2008. Acupuncture and related techniques for postoperative pain: a systematic review of randomized controlled trials. Br. J. Anaesth. 101:2151–60 [Google Scholar]
  39. Smeets RJ, Vlaeyen JW, Kester AD, Knottnerus JA. 39.  2006. Reduction of pain catastrophizing mediates the outcome of both physical and cognitive-behavioral treatment in chronic low back pain. J. Pain 7:4261–71 [Google Scholar]
  40. Boris-Karpel S. 40.  2010. Policy and practice issues in pain management. Behavioral and Psychopharmacologic Pain Management MH Ebert, RD Kerns New York: Cambridge Univ. Press [Google Scholar]
  41. Freye E. 41.  2008. Opioids in Medicine. A Comprehensive Review on the Mode of Action and the Use of Analgesics in Different Clinical Pain States Dordrecht, Neth.: Springer
  42. Zubieta JK, Smith YR, Bueller JA. 42.  et al. 2001. Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science 293:5528311–15 [Google Scholar]
  43. Pattinson KT. 43.  2008. Opioids and the control of respiration. Br. J. Anaesth. 100:6747–58 [Google Scholar]
  44. Volkow ND, McLellan AT. 44.  2016. Opioid abuse in chronic pain—misconceptions and mitigation strategies. N. Engl. J. Med. 374:131253–63 [Google Scholar]
  45. Butler SF, Black RA, Cassidy TA. 45.  et al. 2011. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct. J. 8:29 [Google Scholar]
  46. Mastropietro DJ, Omidian H. 46.  2015. Abuse-deterrent formulations. Pt. 2: Commercial products and proprietary technologies. Expert Opin. Pharmacother. 16:3305–23 [Google Scholar]
  47. Raffa RB, Pergolizzi JV Jr.. 47.  2010. Opioid formulations designed to resist/deter abuse. Drugs 70:131657–75 [Google Scholar]
  48. Bailey CP, Connor M. 48.  2005. Opioids: cellular mechanisms of tolerance and physical dependence. Curr. Opin. Pharmacol. 5:160–68 [Google Scholar]
  49. Roeckel LA, Le Coz GM, Gaveriaux-Ruff C, Simonin F. 49.  2016. Opioid-induced hyperalgesia: cellular and molecular mechanisms. Neuroscience 338:160–82 [Google Scholar]
  50. Williams JT, Christie MJ, Manzoni O. 50.  2001. Cellular and synaptic adaptations mediating opioid dependence. Physiol. Rev. 81:1299–343 [Google Scholar]
  51. Kornetsky C, Bain G. 51.  1968. Morphine: single-dose tolerance. Science 162:38571011–12 [Google Scholar]
  52. Cortazzo MH, Fishman SM. 52.  2008. Major opioids and chronic opioid therapy. In Raj's Practical Management of Pain HT Benzon, JP Rathmell, CL Wu, et al., 597–611 Philadelphia: Mosby Elsevier, 4th ed.. [Google Scholar]
  53. Wax P, Ruha A-M. 53.  2003. Withdrawal syndromes. Opioid withdrawal. Irwin and Rippe's Intensive Care Medicine RS Irwin, JM Rippe Philadelphia: Lippincott Williams & Wilkins, 5th ed.. [Google Scholar]
  54. Ling GS, Paul D, Simantov R, Pasternak GW. 54.  1989. Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model. Life Sci 45:181627–36 [Google Scholar]
  55. Hill R, Lyndon A, Withey S. 55.  et al. 2016. Ethanol reversal of tolerance to the respiratory depressant effects of morphine. Neuropsychopharmacology 41:3762–73 [Google Scholar]
  56. Arout CA, Edens E, Petrakis IL, Sofuoglu M. 56.  2015. Targeting opioid-induced hyperalgesia in clinical treatment: neurobiological considerations. CNS Drugs 29:6465–86 [Google Scholar]
  57. Miller M, Barber CW, Leatherman S. 57.  et al. 2015. Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. JAMA Intern. Med. 175:4608–15 [Google Scholar]
  58. 58. Centers for Disease Control and Prevention. 2013. Number of poisoning deaths involving opioid analgesics and other drugs or substances—United States, 1999–2010. Morb. Mortal. Wkly. Rep. 62:234 [Google Scholar]
  59. Von Korff M, Saunders K, Thomas Ray G. 59.  et al. 2008. De facto long-term opioid therapy for noncancer pain. Clin. J. Pain 24:6521–27 [Google Scholar]
  60. Jones CM, Paulozzi LJ, Mack KA. 60. Centers for Disease Control and Prevention. 2014. Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse-related emergency department visits and drug-related deaths—United States, 2010. Morb. Mortal. Wkly. Rep 63:40881–85 [Google Scholar]
  61. Hall AJ, Logan JE, Toblin RL. 61.  et al. 2008. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 300:222613–20 [Google Scholar]
  62. Correa D, Farney RJ, Chung F. 62.  et al. 2015. Chronic opioid use and central sleep apnea: a review of the prevalence, mechanisms, and perioperative considerations. Anesth. Analg. 120:61273–85 [Google Scholar]
  63. Darke S, Kaye S, Duflou J. 63.  2006. Systemic disease among cases of fatal opioid toxicity. Addiction 101:91299–305 [Google Scholar]
  64. Cheatle MD. 64.  2011. Depression, chronic pain, and suicide by overdose: on the edge. Pain Med 12:Suppl. 2S43–S48 [Google Scholar]
  65. Madadi P, Persaud N. 65.  2014. Suicide by means of opioid overdose in patients with chronic pain. Curr. Pain Headache Rep. 18:11460 [Google Scholar]
  66. Wheeler E, Jones TS, Gilbert MK, Davidson PJ. 66. , Centers for Disease Control and Prevention. 2015. Opioid overdose prevention programs providing naloxone to laypersons—United States, 2014. Morb. Mortal. Wkly. Rep 64:23631–35 [Google Scholar]
  67. Ewan EE, Martin TJ. 67.  2013. Analgesics as reinforcers with chronic pain: evidence from operant studies. Neurosci. Lett. 557:Pt. A60–64 [Google Scholar]
  68. Hou YY, Cai YQ, Pan ZZ. 68.  2015. Persistent pain maintains morphine-seeking behavior after morphine withdrawal through reduced MeCP2 repression of GluA1 in rat central amygdala. J. Neurosci. 35:83689–700 [Google Scholar]
  69. Zhang Z, Tao W, Hou YY. 69.  et al. 2014. Persistent pain facilitates response to morphine reward by downregulation of central amygdala GABAergic function. Neuropsychopharmacology 39:92263–71 [Google Scholar]
  70. Volkow ND, Koob GF, McLellan AT. 70.  2016. Neurobiologic advances from the brain disease model of addiction. N. Engl. J. Med. 374:4363–71 [Google Scholar]
  71. Banta-Green CJ, Merrill JO, Doyle SR. 71.  2009. Opioid use behaviors, mental health and pain—development of a typology of chronic pain patients. Drug Alcohol Depend 104:1–234–42 [Google Scholar]
  72. Fishbain DA, Cole B, Lewis J. 72.  et al. 2008. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med 9:4444–59 [Google Scholar]
  73. Vowles KE, McEntee ML, Julnes PS. 73.  2015. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain 156:4569–76 [Google Scholar]
  74. Compton WM, Jones CM, Baldwin GT. 74.  2016. Nonmedical prescription-opioid use and heroin use. N. Engl. J. Med. 374:131296 [Google Scholar]
  75. Volkow ND, Morales M. 75.  2015. The brain on drugs: from reward to addiction. Cell 162:4712–25 [Google Scholar]
  76. Woody GE. 76.  2017. Advances in the treatment of opioid use disorders. F1000Research 6:87 [Google Scholar]
  77. Korthuis PT, McCarty D, Weimer M. 77.  et al. 2017. Primary care-based models for the treatment of opioid use disorder: a scoping review. Ann. Intern. Med. 166:4268–78 [Google Scholar]
  78. Mistry CJ, Bawor M, Desai D. 78.  et al. 2014. Genetics of opioid dependence: a review of the genetic contribution to opioid dependence. Curr. Psychiatry Rev. 10:2156–67 [Google Scholar]
  79. Conrod PJ, Nikolaou K. 79.  2016. Annual research review: on the developmental neuropsychology of substance use disorders. J. Child Psychol. Psychiatry 57:3371–94 [Google Scholar]
  80. 80. American Psychiatric Association. 2013. Diagnostic and Statistical Manual of Mental Disorders Washington, DC: Am. Psychiatr. Assoc, 5th ed..
  81. McLellan AT, Skipper GS, Campbell M, DuPont RL. 81.  2008. Five year outcomes in a cohort study of physicians treated for substance use disorders in the United States. BMJ 337:a2038 [Google Scholar]
  82. 82. Office of the Surgeon General. 2016. Facing Addiction in America. The Surgeon General's Report on Alcohol, Drugs, and Health. Washington, DC: US Dep. Health Hum. Serv.
  83. Weiss RD, Potter JS, Griffin ML. 83.  et al. 2015. Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study. Drug Alcohol Depend 150:112–19 [Google Scholar]
  84. Manchikanti L, Helm S 2nd, Fellows B. 84.  et al. 2012. Opioid epidemic in the United States. Pain Physician 15:3 Suppl.ES9–ES38 [Google Scholar]
  85. Abeles AM, Pillinger MH, Solitar BM, Abeles M. 85.  2007. Narrative review: the pathophysiology of fibromyalgia. Ann. Intern. Med. 146:10726–34 [Google Scholar]
  86. Keller A, Hayden J, Bombardier C, van Tulder M. 86.  2007. Effect sizes of non-surgical treatments of non-specific low-back pain. Eur. Spine J. 16:111776–88 [Google Scholar]
  87. Geneen LJ, Moore RA, Clarke C. 87.  et al. 2017. Physical activity and exercise for chronic pain in adults: an overview of Cochrane Reviews. Cochrane Database Syst. Rev. 1:CD011279 [Google Scholar]
  88. Zhai J, Zhang L, Li M. 88.  et al. 2015. Epidural injection with or without steroid in managing chronic low-back and lower extremity pain: a meta-analysis of 10 randomized controlled trials. Am. J. Ther. 24:3e259–69 [Google Scholar]
  89. Richette P, Latourte A, Frazier A. 89.  2015. Safety and efficacy of paracetamol and NSAIDs in osteoarthritis: Which drug to recommend?. Expert Opin. Drug Saf. 14:81259–68 [Google Scholar]
  90. Jones T, Moore T, Levy JL. 90.  et al. 2012. A comparison of various risk screening methods in predicting discharge from opioid treatment. Clin. J. Pain 28:293–100 [Google Scholar]
  91. Arnold RM, Han PK, Seltzer D. 91.  2006. Opioid contracts in chronic nonmalignant pain management: objectives and uncertainties. Am. J. Med. 119:4292–96 [Google Scholar]
  92. Fishman SM, Bandman TB, Edwards A, Borsook D. 92.  1999. The opioid contract in the management of chronic pain. J. Pain Symptom Manag. 18:127–37 [Google Scholar]
  93. Tobin DG, Keough Forte K, Johnson McGee S. 93.  2016. Breaking the pain contract: a better controlled-substance agreement for patients on chronic opioid therapy. Cleve. Clin. J. Med. 83:11827–35 [Google Scholar]
  94. Delcher C, Wagenaar AC, Goldberger BA. 94.  et al. 2015. Abrupt decline in oxycodone-caused mortality after implementation of Florida's Prescription Drug Monitoring Program. Drug Alcohol Depend 150:63–68 [Google Scholar]
  95. Paulozzi LJ, Kilbourne EM, Desai HA. 95.  2011. Prescription drug monitoring programs and death rates from drug overdose. Pain Med 12:5747–54 [Google Scholar]
  96. Surratt HL, O'Grady C, Kurtz SP. 96.  et al. 2014. Reductions in prescription opioid diversion following recent legislative interventions in Florida. Pharmacoepidemiol. Drug Saf. 23:3314–20 [Google Scholar]
  97. Coplan PM, Chilcoat HD, Butler SF. 97.  et al. 2016. The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting. Clin. Pharmacol. Ther. 100:3275–86 [Google Scholar]
  98. O'Malley PG, Jackson JL, Santoro J. 98.  et al. 1999. Antidepressant therapy for unexplained symptoms and symptom syndromes. J. Fam. Pract. 48:12980–90 [Google Scholar]
  99. Chou R, Peterson K. 99.  2005. Drug class review on skeletal muscle relaxants Final rep., Oregon Health Sci. Univ. Portland, OR:
/content/journals/10.1146/annurev-med-011817-044739
Loading
/content/journals/10.1146/annurev-med-011817-044739
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error